Please note: This review reflects information we gathered on the date it was researched and may now be out of date. Providers frequently change their pricing, plans, medications, and policies. Any ratings, reviews, and customer feedback are gathered from publicly available online sources and may have since changed or no longer be accurate. Always do your own research and confirm the latest details directly with the provider before making any decision.
Luvo Health Review
They write about this more honestly than anyone else in the category. That does not make the underlying idea right.
Luvo Health
Careful Copy, Unproven PremiseCredit first, and we checked before giving it: we searched specifically for BPC-157, ipamorelin, CJC-1295, epitalon and TB-500 — the peptides that fill this industry. None appear. And their copy is genuinely restrained: "This is a description of mechanism. It is not a promise of a specific effect, and we won't attach benefit claims or timelines to it." Almost nobody here writes that.
But the premise runs against the biology: reduced growth hormone and IGF-1 signalling is associated with longer life in model organisms; humans with GH receptor deficiency show notably low cancer and diabetes rates; and higher IGF-1 has been linked observationally to several cancers. Sermorelin is gentler than hGH and no long-term human trials exist either way — but if you are buying this to live longer, the literature may point the other direction.
And there is no lab testing: "Luvo's evaluation is based on your health history and goals; it does not include lab testing." Honest to disclose, and still a gap — IGF-1 is both the titration guide and the safety signal for growth-hormone-axis therapy. Get your own baseline bloods through your regular clinician before starting.
Affiliate disclosure — read this one: This programme pays GLP1Drugs.org a flat $200 per conversion. Sermorelin and NAD+ cost $199 for four weeks, so our commission is larger than your entire first month. That is the biggest incentive attached to anything we have reviewed, which is exactly why this page spends most of its length on the evidence problem. Verified 8 August 2026.
Visit Luvo HealthOur Top Recommended Provider: CoreAge Rx
After reviewing dozens of GLP-1 telehealth providers, CoreAge Rx is the one we recommend most. CoreAge Rx is one of our partners — read on for why we recommend them:
Flat-Rate Pricing
Same cost at every dose level — no price jumps as you titrate up.
Verified Pharmacies
US-licensed physicians and NABP-verified 503A compounding pharmacies you can trust.
Everything Included
Medication, supplies, free shipping, and ongoing clinical support — no hidden fees.
Active Community of Members
Ask questions, share progress, and get answers from other patients on the same journey — alongside ongoing clinical support from your care team.
$200
Our Commission
$199
Your First Four Weeks
$2,587
A Year, At 13 Four-Week Cycles
0
Long-Term Outcome Trials
What We Verified
Quotes read from Luvo's own longevity pages and price table on 8 August 2026. We searched their pages by name for the peptides we expected to find, and report that we did not find them.
They Avoid The Peptides FDA Flagged, And We Checked
We searched their longevity pages specifically for BPC-157, ipamorelin, CJC-1295, epitalon and TB-500 — the peptides that fill this industry and that FDA has treated as posing significant compounding safety risks. None appear. What they sell is sermorelin, NAD+ and vitamin B12/MIC. That is a real point in their favour
The Copy Is More Disciplined Than The Category Norm
On sermorelin's mechanism they write: "This is a description of mechanism. It is not a promise of a specific effect, and we won't attach benefit claims or timelines to it." Almost nobody in longevity marketing writes that sentence. "Compounded medications are not FDA-approved" appears repeatedly as a standing disclaimer
And They Are Straight About The Regulatory History
"Sermorelin was once an FDA-approved medication, marketed as Geref. In 2008 the manufacturer discontinued it for business reasons, not because of a safety problem." That is accurate. They then state plainly that "compounded sermorelin is not FDA-approved" and that a provider explains this before prescribing
They Also Concede The Decline Is Not A Disease
"Growth hormone production naturally declines with age. This is a normal part of how the endocrine system changes over time, not a disease." That sentence undercuts the usual anti-ageing sales pitch, and they printed it anyway. Credit where it is due
But There Is No Lab Testing
"Luvo's evaluation is based on your health history and goals; it does not include lab testing." They disclose it, which is honest — and it is still a gap. IGF-1 is the parameter you would normally measure before and during growth-hormone-axis therapy, both to titrate and as the safety signal
$199 Per Four Weeks — And We Are Paid $200
Sermorelin, NAD+ injection, NAD+ drops and NAD+ spray each list at $199 for four weeks, with longer prepaid terms at $507, $894 and $1,417. On a four-week cycle that is roughly $2,587 a year. This programme pays us $200 per conversion — more than your entire first month costs
The Growth Hormone Axis, Both Directions
We are laying out the tension rather than pretending it resolves. General scientific background, not medical advice.
| The Commercial Logic | What The Ageing Literature Suggests |
|---|---|
| Growth hormone falls with age, so restore it | Reduced GH/IGF-1 signalling is associated with longer life in model organisms |
| More growth hormone means more vitality | Humans with GH receptor deficiency have been reported to show very low cancer and diabetes rates |
| Raising IGF-1 is the goal | Higher IGF-1 has been linked observationally to several cancers |
| In fairness to sermorelin | It prompts pulsatile release rather than flooding the system, effects are modest, and no long-term human trial exists in either direction |
None of that is proof of harm, and model organisms are not people. It is a reason to treat "longevity" as a marketing category rather than a demonstrated outcome — and to ask your own clinician, with your own bloods in front of them, rather than a website.
If You Are Here About Muscle Loss
The most likely reason a GLP-1 patient lands on a growth hormone product. We earn nothing on any of this.
| Approach | Evidence For Preserving Lean Mass | Cost |
|---|---|---|
| Resistance training, 2+ times a week | The best-supported intervention there is | Free to low |
| Adequate protein | Well established; hard on a collapsed appetite, which is the real problem to solve | Grocery budget |
| Baseline and follow-up bloods | Not a treatment, but the measurement this service omits | Modest, via your own clinician |
| Sermorelin subscription | No long-term human outcome trials for healthspan or lean-mass preservation on a GLP-1 | ~$2,587/yr |
Tell your prescribing clinician about anything you add to a GLP-1 regimen. Our side-effects guide and cost guide cover the ground this subscription is priced against.
Pros & Cons
Pros
- ✓None of the FDA-flagged compounding peptides — no BPC-157, ipamorelin, CJC-1295, epitalon or TB-500 — appear in their longevity range
- ✓"Compounded medications are not FDA-approved" is stated repeatedly rather than buried once in a footer
- ✓Explicit refusal to make outcome claims: "we won't attach benefit claims or timelines to it"
- ✓Accurate account of sermorelin's history, including that Geref was withdrawn commercially rather than for safety
- ✓States openly that age-related growth hormone decline "is a normal part of how the endocrine system changes over time, not a disease"
- ✓Discloses the absence of lab testing rather than letting patients assume it happens
- ✓"No commitment until clinician review" and "Cancel anytime" are stated on the programme page
- ✓Prescription-only, with a licensed provider reviewing history before anything is dispensed
- ✓A published price list covering every product and term, which is rarer in this category than it should be
Cons
- ✕The core premise — stimulating the growth hormone axis to extend healthy life — runs against much of the biology-of-ageing literature
- ✕No long-term outcome trials exist showing sermorelin extends healthspan or lifespan in humans
- ✕No lab testing means no baseline IGF-1, which is both the titration guide and the safety signal for GH-axis therapy
- ✕Injectable NAD+ has no demonstrated clinical longevity outcome in humans; the evidence is preliminary
- ✕NAD+ sold as drops and nasal spray raises absorption questions the pages do not address
- ✕$199 per four weeks is roughly $2,587 a year on a 13-cycle basis, for an unproven indication
- ✕Compounded means not FDA-approved: not reviewed for safety, efficacy or quality
- ✕They also sell compounded semaglutide and tirzepatide, which carry the separate regulatory problems we cover elsewhere
- ✕Enclomiphene at $189 is likewise not an FDA-approved product
- ✕The $200 commission exceeds the first month's price, which is the largest incentive in anything we have reviewed
Our Verdict
3.0 / 5 — the most careful writing in the category, attached to a premise the evidence does not support.
We approached this one expecting the worst, because the longevity peptide business generally deserves it, and because the affiliate payout here is the largest we have ever been offered. So we started by searching their pages by name for the compounds that populate this industry: BPC-157, ipamorelin, CJC-1295, epitalon, thymosin beta-4. FDA has treated these as presenting significant risks when compounded, and a great many clinics sell them anyway. None of them appear anywhere in Luvo's longevity range. What they sell is sermorelin, NAD+ in three formats, and a vitamin B12/MIC injection. That is a materially different and more defensible catalogue, and having gone looking for a reason to condemn them we would be dishonest not to lead with what we actually found.
The writing is more impressive still. On the mechanism of sermorelin they write: "This is a description of mechanism. It is not a promise of a specific effect, and we won't attach benefit claims or timelines to it." On the premise underneath the whole product category: growth hormone decline "is a normal part of how the endocrine system changes over time, not a disease" — a sentence that actively undermines the standard anti-ageing pitch, printed on their own page. On regulatory status they give an accurate history, noting that sermorelin was approved as Geref and that "in 2008 the manufacturer discontinued it for business reasons, not because of a safety problem", before stating plainly that "compounded sermorelin is not FDA-approved" and that a provider explains this before prescribing. "Compounded medications are not FDA-approved" recurs as a standing disclaimer rather than appearing once in small type. And most tellingly, they volunteer a weakness: "Luvo's evaluation is based on your health history and goals; it does not include lab testing." Companies do not usually publish the sentences that cost them sales.
Then there is the problem that careful writing cannot solve, and it is the reason this is a three rather than a four. The growth hormone axis is one of the few areas in ageing research where the evidence runs fairly consistently against the commercial logic. Reduced growth hormone and IGF-1 signalling is associated with extended lifespan across model organisms. In humans, people with growth hormone receptor deficiency have been reported to show strikingly low rates of cancer and diabetes. Higher circulating IGF-1 has been linked in observational work to increased risk of several cancers, including prostate, breast and colorectal. So a product whose mechanism is stimulating that axis is being sold as a longevity intervention in a field where less signalling, not more, is what correlates with living longer. We are not claiming this proves sermorelin is harmful, and we want to be scrupulous about that: sermorelin prompts pulsatile, physiological release rather than flooding the body with exogenous hormone, the effects are modest, animal models are not people, observational associations are not causation, and there are no long-term human outcome trials in either direction. Nobody can tell you it works and nobody can tell you it hurts. But a buyer whose goal is a longer life deserves to know that the underlying literature is contested at best.
The missing lab testing compounds it. IGF-1 is the parameter clinicians follow when managing growth-hormone-axis therapy: it is how a dose is titrated to a sensible range, and it is the safety signal that tells you when you have pushed someone too far above normal for their age. Starting a growth hormone secretagogue with no baseline IGF-1 means beginning without the measurement you would use to judge either efficacy or safety, and the same objection applies with more force to the testosterone and enclomiphene they sell elsewhere. Luvo disclose the absence honestly, which is why this is a criticism rather than an accusation — but the fix is on you, and it is worth doing: get baseline bloods through your own clinician, and repeat them, so somebody with your full record can see what is happening. On NAD+, the molecule and its age-related decline are real, and Luvo describe both accurately without overclaiming. What has not been established is that raising it produces meaningful clinical benefit, let alone longevity; and selling the same nominal product as injection, sublingual drops and nasal spray at the same $199 invites the obvious question of whether all three deliver comparable amounts of a large, charged molecule into circulation. The pages do not address it.
On cost: sermorelin and each NAD+ format list at $199 for four weeks, with longer prepaid terms at $507, $894 and $1,417. Four weeks is not a month — a 52-week year contains thirteen such cycles, so the headline rate annualises to about $2,587 rather than $2,388. For a GLP-1 reader, the likeliest route here is anxiety about lean mass, and it deserves a direct answer: the interventions with evidence behind them for preserving muscle during weight loss are resistance training at least twice a week and adequate protein, neither of which this replaces, and if you can only afford one thing, buy the gym membership. Finally, our disclosure, which we have deliberately put in three places on this page. This programme pays a flat $200 per conversion — more than the $199 your first four weeks cost, and many times what any other merchant in this batch pays us. An advertiser willing to spend more than a full billing cycle on acquisition is one that expects long subscription tenure. And an affiliate with a $200 incentive is one you should read sceptically. That is exactly why this review spends its length on the evidence rather than the offer, and why our actual recommendation — get your own bloods, do the resistance training, treat longevity as a marketing category until someone shows you an outcome trial — earns us nothing at all.
Visit Luvo HealthFrequently Asked Questions
What does Luvo actually sell under longevity?
Four things, and notably not the ones we went looking for. The longevity range is sermorelin injection, NAD+ in three formats — injection, sublingual drops and nasal spray — and a vitamin B12/MIC injection. Sermorelin, NAD+ injection, NAD+ drops and NAD+ spray each list at $199 for four weeks, with longer prepaid terms shown at $507, $894 and $1,417. Elsewhere on the site they sell compounded semaglutide and tirzepatide for weight loss, microdosing versions of both at $179, testosterone injection at $199, enclomiphene at $189, gonadorelin at $35 and a skincare line at $99 a month. Here is what we checked first and what we found, because it matters. The longevity peptide industry is largely built on compounds that FDA has treated as presenting significant risks when compounded — BPC-157, ipamorelin, CJC-1295, epitalon, thymosin beta-4. We searched their pages specifically for each of those names. None of them appear. That is a genuine and meaningful difference from a great many competitors, and we would rather report it than imply guilt by category. What they do sell sits in a more defensible place: sermorelin was an approved drug once, and NAD+ is a naturally occurring coenzyme rather than a designer peptide. That does not make either of them proven, and the rest of this review explains why we still landed at three out of five. But the first question about a longevity clinic is usually whether it is selling grey-market research chemicals, and the answer here is no.
Why do you say the biology argues against the premise?
Because in ageing research, the growth hormone axis is one of the few places where the evidence points fairly consistently in the opposite direction from the marketing. Here is the tension, stated as carefully as we can. The commercial logic of GH-axis therapy is intuitive: growth hormone declines with age, ageing is bad, therefore restoring growth hormone should be good. Luvo, to their credit, explicitly declines the first move — they write that the decline "is a normal part of how the endocrine system changes over time, not a disease". But the deeper problem is that reduced growth hormone and IGF-1 signalling is robustly associated with longer life across model organisms, not shorter. In humans, people with growth hormone receptor deficiency have been reported to show strikingly low rates of cancer and diabetes. And observational studies have linked higher circulating IGF-1 to increased risk of certain cancers, including prostate, breast and colorectal. So the axis being stimulated here is one where a substantial body of research associates less signalling with longevity, not more. We want to be fair about the limits of that argument. Sermorelin works by prompting the pituitary to release growth hormone in a more physiological, pulsatile way rather than flooding the system with exogenous hormone, which is a genuinely different thing from injecting hGH. The effects are modest. Model organisms are not people, and observational associations are not causation. Crucially, there are no long-term outcome trials of sermorelin for healthspan or lifespan in either direction — nobody can tell you it works, and nobody can tell you it is harmful over decades. That symmetry is the honest position. But if you are buying this specifically to live longer, you should know the underlying literature is contested at best and arguably points the other way.
Does the missing lab testing matter?
Yes, more than anything else on this page, and they deserve credit for telling you. The disclosure is explicit: "Luvo's evaluation is based on your health history and goals; it does not include lab testing." Publishing that rather than letting patients assume bloods are involved is genuinely honest. It is also a real clinical gap, for a specific reason. When clinicians manage growth-hormone-axis therapy, IGF-1 is the number they follow. It is the practical readout of how much growth hormone activity a treatment is producing, it is how a dose gets titrated to a sensible range, and it is the safety signal — the thing you watch to make sure you have not pushed someone well above the normal range for their age. Prescribing a growth hormone secretagogue without a baseline IGF-1 means starting without the measurement you would normally use to judge both whether it is working and whether it has gone too far. The same argument applies to the rest of their catalogue with more force: testosterone therapy without baseline testosterone, haematocrit and PSA monitoring, or enclomiphene without hormone panels, is not how those medicines are usually managed. Practically, if you decide to proceed, the sensible move is to get your own baseline bloods through your regular clinician before you start — IGF-1 at minimum for sermorelin — and repeat them, so that you and someone with access to your full record can see what is happening. It costs relatively little, it is the missing half of the service, and we earn nothing for suggesting it.
What about NAD+ drops and nasal spray?
The molecule is real and important; the delivery and the outcome claims are where the evidence thins out. NAD+ is nicotinamide adenine dinucleotide, a coenzyme central to energy metabolism and to the function of enzymes involved in DNA repair and cellular signalling. Luvo's own description of what it does is accurate and appropriately dry — they say research indicates NAD+ levels change with age, which is fair, and they avoid promising outcomes. Where scepticism belongs is in the two steps after that. First, the inference that because a molecule declines with age, supplementing it will improve health outcomes, is exactly the reasoning that has repeatedly failed elsewhere in nutrition and hormone science; it needs testing rather than assuming. Human trials of NAD+ precursors have shown that you can raise measurable NAD+ levels, which is a biomarker result, but demonstrating that this translates into meaningful clinical benefit — let alone longevity — is a different and much harder thing that has not been established. Second, delivery. NAD+ is a large, charged molecule, which is precisely why intravenous administration became the fashionable route; whether a sublingual drop or a nasal spray delivers a meaningful quantity into circulation is a question the product pages do not address, and it is the question that determines whether you are buying anything at all. If a company sells the same nominal product as injection, drops and spray at the same $199 price, it is reasonable to ask whether all three do the same thing. So: NAD+ is not snake oil, the biology is genuine, and the clinical case for buying it as a consumer product at $2,500 a year is not made. If you want to explore it, ask specifically what evidence supports the format you are being sold.
What does it cost in total?
About $2,587 a year at the headline rate, and the tiering rewards prepaying. Sermorelin, NAD+ injection, NAD+ drops and NAD+ spray each list at $199 for four weeks. Note the interval: four weeks is not a month. A 52-week year holds thirteen four-week cycles, not twelve, so the true annual cost at that rate is thirteen times $199, or $2,587 — not the $2,388 you get by reading it as monthly. Longer prepaid terms are listed at $507, $894 and $1,417, which reduce the effective rate substantially for anyone willing to commit up front, though committing up front is precisely what you should be slowest to do with an unproven intervention. We read those figures from their published price table; we did not go through checkout, so we cannot confirm what a specific term covers or whether shipping and consultation are included in every case. For comparison within their own catalogue, tirzepatide injection is $339 per four weeks, microdosing semaglutide or tirzepatide $179, testosterone injection $199, enclomiphene $189 and gonadorelin $35. Two things to do before committing. Ask what the total is at the point you would realistically stop — this is a subscription for a condition that does not resolve, so the honest budgeting horizon is years, not a trial month. And ask what would cause your clinician to recommend stopping, because a longevity programme with no stopping criterion is a subscription rather than a treatment.
Is any of this relevant if I am on a GLP-1?
Two ways, one of them a genuine caution. The first is straightforward: Luvo also sells compounded semaglutide and tirzepatide, including microdosing versions at $179 per four weeks. Everything we have written elsewhere about compounded GLP-1s applies here without modification — compounded means not FDA-approved and not reviewed by FDA for safety, efficacy or quality; the shortages that justified mass compounding were declared resolved in December 2024 and February 2025; and the manufacturers now sell FDA-approved product direct to self-paying patients at prices that frequently undercut compounded routes. Price the approved options before the compounded ones. The second is more specific and worth raising because nobody else will. If you are losing a substantial amount of weight on a GLP-1, you are losing some lean mass along with fat, and that is exactly the anxiety a growth hormone product is well positioned to sell against. It would be very easy to read "supports metabolic health" and "preserving it for the years ahead" as an answer to muscle loss. It is not an established one. The interventions with actual evidence behind them for preserving lean mass during weight loss remain unglamorous: progressive resistance training at least twice a week, and adequate protein, which is hard when appetite has collapsed but is where the evidence sits. Adding a $2,587-a-year hormone subscription is not a substitute for either, and if you can only do one thing, do the lifting. Talk to your prescribing clinician before adding any hormone therapy to a GLP-1 regimen, and tell them about everything you are taking.
How should I read your $200 commission here?
Sceptically, and we would rather say so loudly than let you find out later. This programme pays GLP1Drugs.org a flat $200 for a conversion. That is the largest single payout of anything we have reviewed, by a wide margin — most of the merchants in this batch pay us between two and ten per cent of an order, which typically works out at a few dollars. Two hundred dollars is more than the $199 that a customer's first four weeks costs. Think about what that implies from the company's side: an advertiser willing to pay more than a full billing cycle to acquire a customer expects that customer to stay for many cycles, which tells you the business model assumes long-duration subscription revenue from a product with no defined endpoint. And think about what it implies from ours: every incentive we have points towards writing an enthusiastic review, minimising the evidence problem, and encouraging you to sign up. That is precisely why this review spends most of its length on why the underlying premise is contested, why the absence of lab testing matters, and why you should get your own baseline bloods elsewhere. We would rather publish an honest three out of five and earn nothing than take $200 for a recommendation we do not believe. If you take one thing from this page, let it be the general principle rather than anything about this company: when an affiliate payout exceeds the first month's price, read the review that recommends it very carefully indeed, wherever you find it.
What is your verdict?
3.0 out of 5 — the most carefully written copy we have seen in this category, attached to a premise the evidence does not support. We will start with the credit, because it is substantial and unusual. We came to this expecting the standard longevity-clinic catalogue of grey-market peptides, and searched specifically for BPC-157, ipamorelin, CJC-1295, epitalon and thymosin beta-4 — the compounds FDA has treated as presenting significant risks in compounding. Not one of them appears. What Luvo sells is sermorelin, NAD+ and B12/MIC. More striking is how they write about it. On sermorelin's mechanism: "This is a description of mechanism. It is not a promise of a specific effect, and we won't attach benefit claims or timelines to it." On the underlying rationale: growth hormone decline "is a normal part of how the endocrine system changes over time, not a disease". On regulatory status, an accurate account of Geref's commercial withdrawal in 2008 followed by a plain statement that "compounded sermorelin is not FDA-approved". And an unprompted admission that the service "does not include lab testing". Companies do not usually print the sentences that weaken their own sales pitch. Against that sits the problem no amount of good copywriting fixes. The growth hormone axis is one of the clearest places in ageing research where the evidence runs against the commercial logic: reduced GH and IGF-1 signalling is associated with longer life in model organisms, humans with GH receptor deficiency show notably low cancer and diabetes rates, and higher IGF-1 has been linked observationally to several cancers. Sermorelin is gentler than exogenous hGH and no long-term human outcome trials exist in either direction — so this is a reason for caution rather than a finding of harm. But if the purchase is specifically to live longer, the buyer deserves to know the literature may point the other way. Add injectable and intranasal NAD+ whose clinical benefit is unestablished, the missing IGF-1 baseline, and $199 per four weeks — roughly $2,587 a year on the thirteen-cycle basis — and this is an expensive subscription for an unproven end. Our disclosure, which should shape how you read all of it: $200 per conversion, more than your first month costs, and nothing at all if you follow our actual advice, which is to get baseline bloods through your own clinician and spend the money on resistance training first.
Get The Bloods First.
This service does not include lab testing, and IGF-1 is both how a dose is titrated and how safety is watched. Get a baseline through your own clinician before starting — and remember we are paid $200 while your first month costs $199.
Visit Luvo HealthCompare Other GLP-1 Providers
See how other telehealth providers stack up.
Mochi Health
Obesity Medicine SpecialistsBoard-certified obesity medicine specialists with both brand-name and compounded GLP-1 options
Read Review →Henry Meds
Top RatedWell-established telehealth platform with fast physician reviews and competitive pricing
Read Review →CoreAge Rx
#1 RecommendedFlat-rate pricing for compounded semaglutide and tirzepatide with NABP-verified pharmacies
Read Review →Form Health
Comprehensive ProgramMultidisciplinary obesity medicine program with physicians, dietitians, and behavioral coaching
Read Review →GoodRx Care
Trusted BrandTelehealth platform from GoodRx with transparent pricing and established trust
Read Review →Alan Meds
Top RatedAffordable compounded GLP-1s with board-certified physicians and straightforward pricing
Read Review →Medical Disclaimer: This page is informational and is not medical advice, a diagnosis, or a recommendation for or against any treatment or provider. Sermorelin, NAD+ preparations, testosterone, enclomiphene and gonadorelin are prescription products; compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality. Only a licensed clinician with access to your full history can decide whether any of these is appropriate for you. Growth hormone secretagogue therapy is not appropriate for everyone and may be contraindicated in active malignancy and in other circumstances; anyone with a personal or family history of cancer should raise this specifically with a clinician before considering it. Statements about associations between growth hormone or IGF-1 signalling and longevity, cancer risk, or growth hormone receptor deficiency are general summaries of a scientific literature that is largely drawn from model organisms and observational human studies; associations are not causation, findings in model organisms do not necessarily apply to people, and nothing here establishes that any product is harmful or beneficial. There are no long-term human outcome trials of sermorelin for healthspan or lifespan in either direction. Do not start, stop or change any prescribed medication on the basis of this page, and tell your prescribing clinician about every medication and supplement you take, particularly before adding hormone therapy to a GLP-1 regimen. Guidance on resistance training and protein intake is general and should be tailored by a clinician, dietitian or physiotherapist; protein requirements are affected by kidney function and other conditions. Prices quoted are the seller's published figures on the date stated and may change. Consult a licensed clinician before starting or changing any treatment.
Date reviewed: 8 August 2026. All Luvo Health quotations and prices were read from luvohealth.com on that date. The longevity programme page listed the following products: 'Longevity Injection Vitamin B12/MIC', 'Longevity Spray NAD+ Spray', 'Longevity Drops NAD+ Drops', 'Longevity Injection NAD+ Injection' and 'Longevity Injection Sermorelin', with the standing notices 'Images are for illustrative purposes only. Individual results may vary.' and 'Compounded medications are not FDA-approved.' The page also stated 'No commitment until clinician review' and 'Cancel anytime'. Quoted verbatim from their sermorelin material: 'This is a description of mechanism. It is not a promise of a specific effect, and we won't attach benefit claims or timelines to it.'; 'Sermorelin was once an FDA-approved medication, marketed as Geref. In 2008 the manufacturer discontinued it for business reasons, not because of a safety problem. That distinction matters: the withdrawal was a commercial decision.'; 'Today sermorelin is available as a compounded medication, prepared by a licensed compounding pharmacy for an individual patient based on a provider's prescription. To be clear about what that means: compounded sermorelin is not FDA-approved. A licensed provider explains this before anything is prescribed.'; 'Luvo's evaluation is based on your health history and goals; it does not include lab testing.'; and 'Growth hormone production naturally declines with age. This is a normal part of how the endocrine system changes over time, not a disease.' Their NAD+ material stated that 'Research indicates that NAD+ levels change with age' and described NAD+ as a coenzyme in energy metabolism. Prices were read from their published price table, which listed Sermorelin, NAD+ Injection, NAD+ Drops and NAD+ Spray each at $199 under a '4 WEEKS' column, with further tiers at $507, $894 and $1,417; and elsewhere Tirzepatide Injection $339, Microdosing Tirzepatide Injection $179, Microdosing Semaglutide Injection $179, Microdosing Semaglutide Tablets $179, Testosterone Injection $199, Enclomiphene $189, Gonadorelin $35 and skincare formulas at $99 per month. We did not confirm the duration covered by the $507, $894 and $1,417 tiers, and we did not reach a checkout, create an account, complete an intake, consult a clinician or receive any product; we therefore make no assessment of clinical quality, prescriber licensure coverage, shipping or customer service, and cannot confirm what is included in any given price. The annual figure of approximately $2,587 is our own arithmetic, being thirteen four-week cycles in a 52-week year at $199. Absence findings: we searched the longevity pages by name, using word-boundary matching, for BPC-157, ipamorelin, CJC-1295, epitalon, tesamorelin, TB-500 and thymosin, and found no occurrences of any of them; that reflects the pages we read on the date checked and is not a claim about the company's entire catalogue or its future offerings. Scientific background: statements that reduced growth hormone and IGF-1 signalling is associated with extended lifespan in model organisms, that humans with growth hormone receptor deficiency have been reported to show low rates of cancer and diabetes, and that higher circulating IGF-1 has been associated in observational studies with increased risk of certain cancers, are general summaries of published ageing research and are not claims made by Luvo Health, nor do they constitute evidence about the effects of sermorelin specifically, which has not been studied for long-term outcomes in humans. Katalys offer #1633 lists a $200.00 flat default commission.
Affiliate Disclosure: This site may receive compensation from affiliate partners. This programme pays a flat $200.00 per conversion — the largest payout attached to any merchant we have reviewed, and more than the $199 that a customer's first four weeks costs. We have disclosed this in three separate places on this page because an incentive of that size is a reason for readers to discount our enthusiasm, and because our actual recommendations here — obtain baseline bloods through your own clinician, prioritise resistance training and protein, and treat longevity as a marketing category until an outcome trial exists — earn us nothing. This does not influence our editorial content or review ratings.